Skip to Main Content
Table 2.

Demographic characteristics of the study cohort by type of transplant

Entire cohort (n = 845)Type of HCT
Autologous (n = 417)Allogeneic (n = 428)
Age (y), median (range)    
    Age at transplantation 38.2 (21.0-68.6) 42.9 (21.0-68.6) 35.2 (21.1-62.0) 
    Age at study participation 46.3 (23.3-73.0) 49.1 (23.3-73.0) 44.5 (24.2-65.5) 
Gender, n (%)    
    Male 460 (54.4) 222 (53.2) 238 (55.6) 
Race, n (%)    
    White 681 (80.6) 356 (85.4) 325 (75.9) 
    Hispanic 96 (11.4) 36 (8.6) 60 (14.0) 
    Other 68 (8.0) 25 (6.0) 43 (10.1) 
Education, n (%)    
    High school or less 146 (17.3) 65 (15.6) 81 (19.0) 
    High school and some college 314 (37.3) 142 (34.1) 172 (40.4) 
    College degree 382 (45.4) 209 (50.2) 173 (40.6) 
Household income, n (%)    
    ≥$60,000/y 387 (48.4) 205 (52.0) 182 (44.9) 
    $20,000-59,999/y 307 (38.4) 148 (37.6) 159 (39.3) 
    <$20,000/y 105 (13.1) 41 (10.4) 64 (15.8) 
Current health insurance, n (%)    
    Uninsured 54 (6.5) 19 (4.6) 35 (8.3) 
Duration of follow-up (y), n (%)    
    2-5 387 (45.8) 219 (52.5) 168 (39.3) 
    6-10 285 (33.7) 150 (36.0) 135 (31.5) 
    ≥11 173 (20.5) 48 (11.5) 125 (29.2) 
Primary diagnosis    
    Hodgkin's lymphoma 82 (9.7) 79 (18.9) 3 (0.7) 
    Non–Hodgkin's lymphoma 196 (23.2) 172 (41.2) 24 (5.6) 
    Acute lymphoid leukemia 52 (6.2) 8 (1.9) 44 (10.3) 
    Acute myeloid leukemia 188 (22.2) 75 (18.0) 113 (26.4) 
    Chronic myeloid leukemia 223 (26.4) 22 (5.3) 201 (47.0) 
    Aplastic anemia 27 (3.2)  27 (6.3) 
    Other 77 (9.1) 61 (14.7) 16 (3.8) 
Relapse risk at HCT, n (%)    
    High risk 322 (38.2) 194 (46.5) 128 (30.1) 
Conditioning regimen n (%)    
    Total body irradiation 661 (78.5) 281 (67.9) 380 (88.8) 
Chronic graft vs host disease    
    Yes — — 260 (60.9) 
Graft vs host disease prophylaxis/treatment    
    Cyclosporin A — — 321 (75.0) 
Current health, n (%)    
    Fair/poor 173 (20.6) 73 (17.6) 100 (23.4) 
Concerns for future health, n (%)    
    Not concerned 40 (4.9) 28 (6.8) 12 (2.9) 
Entire cohort (n = 845)Type of HCT
Autologous (n = 417)Allogeneic (n = 428)
Age (y), median (range)    
    Age at transplantation 38.2 (21.0-68.6) 42.9 (21.0-68.6) 35.2 (21.1-62.0) 
    Age at study participation 46.3 (23.3-73.0) 49.1 (23.3-73.0) 44.5 (24.2-65.5) 
Gender, n (%)    
    Male 460 (54.4) 222 (53.2) 238 (55.6) 
Race, n (%)    
    White 681 (80.6) 356 (85.4) 325 (75.9) 
    Hispanic 96 (11.4) 36 (8.6) 60 (14.0) 
    Other 68 (8.0) 25 (6.0) 43 (10.1) 
Education, n (%)    
    High school or less 146 (17.3) 65 (15.6) 81 (19.0) 
    High school and some college 314 (37.3) 142 (34.1) 172 (40.4) 
    College degree 382 (45.4) 209 (50.2) 173 (40.6) 
Household income, n (%)    
    ≥$60,000/y 387 (48.4) 205 (52.0) 182 (44.9) 
    $20,000-59,999/y 307 (38.4) 148 (37.6) 159 (39.3) 
    <$20,000/y 105 (13.1) 41 (10.4) 64 (15.8) 
Current health insurance, n (%)    
    Uninsured 54 (6.5) 19 (4.6) 35 (8.3) 
Duration of follow-up (y), n (%)    
    2-5 387 (45.8) 219 (52.5) 168 (39.3) 
    6-10 285 (33.7) 150 (36.0) 135 (31.5) 
    ≥11 173 (20.5) 48 (11.5) 125 (29.2) 
Primary diagnosis    
    Hodgkin's lymphoma 82 (9.7) 79 (18.9) 3 (0.7) 
    Non–Hodgkin's lymphoma 196 (23.2) 172 (41.2) 24 (5.6) 
    Acute lymphoid leukemia 52 (6.2) 8 (1.9) 44 (10.3) 
    Acute myeloid leukemia 188 (22.2) 75 (18.0) 113 (26.4) 
    Chronic myeloid leukemia 223 (26.4) 22 (5.3) 201 (47.0) 
    Aplastic anemia 27 (3.2)  27 (6.3) 
    Other 77 (9.1) 61 (14.7) 16 (3.8) 
Relapse risk at HCT, n (%)    
    High risk 322 (38.2) 194 (46.5) 128 (30.1) 
Conditioning regimen n (%)    
    Total body irradiation 661 (78.5) 281 (67.9) 380 (88.8) 
Chronic graft vs host disease    
    Yes — — 260 (60.9) 
Graft vs host disease prophylaxis/treatment    
    Cyclosporin A — — 321 (75.0) 
Current health, n (%)    
    Fair/poor 173 (20.6) 73 (17.6) 100 (23.4) 
Concerns for future health, n (%)    
    Not concerned 40 (4.9) 28 (6.8) 12 (2.9) 
Close Modal

or Create an Account

Close Modal
Close Modal